TMAO在消化系统恶性肿瘤中的研究进展

doi:10.3969/j.issn.1004-583X.2024.07.015

临床荟萃 ›› 2024, Vol. 39 ›› Issue (7): 664-667.doi: 10.3969/j.issn.1004-583X.2024.07.015

TMAO在消化系统恶性肿瘤中的研究进展

任怀静¹, 陶嘉楠²(), 王学红², 绽永华², 安琪², 张宏琳²

1.青海大学临床医学院,青海西宁 810016
2.青海大学附属医院消化内科,青海西宁 810000

收稿日期:2024-04-07 出版日期:2024-07-20 发布日期:2024-08-02
通讯作者: 陶嘉楠 E-mail:jianan666@hotmail.com
基金资助:
青海大学附属医院中青年科研基金一般项目——CAPS患者血TMAO水平变化及其预后的相关性研究(ASRF-2023-YB-08)

Received:2024-04-07 Online:2024-07-20 Published:2024-08-02

摘要/Abstract

摘要：

消化系统恶性肿瘤发病率高、侵袭性强并且预后差,对人类生存构成严重威胁。氧化三甲胺(trimethylamine-N-oxide,TMAO)是肠道微生物代谢的重要成分,不仅与心房颤动、冠状动脉粥样硬化、心力衰竭、慢性肾脏病和糖尿病等疾病息息相关,还参与参与消化道系统恶性肿瘤的发生发展、侵袭和转移等过程。TMAO有望成为消化系统肿瘤早期诊断、靶向治疗及评估预后的标志物,本文就TMAO异常表达的致癌机制及其在消化系统恶性肿瘤中的研究做一综述。

中图分类号:

R735

任怀静, 陶嘉楠, 王学红, 绽永华, 安琪, 张宏琳. TMAO在消化系统恶性肿瘤中的研究进展[J]. 临床荟萃, 2024, 39(7): 664-667.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.07.015

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I7/664

参考文献 26

[1]	Mizrahi J, Pant S. Immunotherapy in Gastrointestinal Malignancies[J]. Adv Exp Med Biol, 2020, 1244:93-106. doi: 10.1007/978-3-030-41008-7_5 pmid: 32301012
[2]	王昱欢, 吴穹, 马晓峰, 等. 氧化三甲胺在动脉粥样硬化中的研究进展[J]. 中国动脉硬化杂志, 2023, 31(10):901-908.
[3]	Li CY, Chen XL, Zhang D, et al. Structural mechanism for bacterial oxidation of oceanic trimethylamine into trimethylamine N-oxide[J]. Mol Microbiol, 2017, 103(6):992-1003.
[4]	刘恺闻, 张魁, 周宁, 等. 肠道菌群与冠心病关系的研究进展[J]. 中国胸心血管外科临床杂志, 2023, 30(5):746-752.
[5]	Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health[J]. EXCLI J, 2021, 20:301-319. doi: 10.17179/excli2020-3239 pmid: 33746664
[6]	Fennema D, Phillips IR, Shephard EA. Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease[J]. Drug Metab Dispos, 2016, 44(11):1839-1850. pmid: 27190056
[7]	Zhu Y, Li Q, Jiang H. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide[J]. APMIS, 2020, 128(5):353-366. doi: 10.1111/apm.13038 pmid: 32108960
[8]	宫铭, 张成普. 氧化三甲胺与老年常见恶性肿瘤关系的研究进展[J]. 实用老年医学, 2022, 36(1):14-18.
[9]	敦泽, 郭立芳. 幽门螺杆菌致病机制的研究进展[J]. 中国中西医结合消化杂志, 2020, 28(8):645-648.
[10]	Tacconi E, Palma G, De Biase D, et al. Microbiota effect on trimethylamine N-Oxide production: From Cancer to Fitness-a practical preventing recommendation and therapies[J]. Nutrients, 2023, 15(3):563.
[11]	Stonans I, Kuzmina J, Polaka I, et al. The association of circulating L-carnitine, gamma-butyrobetaine and trimethylamine N-oxide levels with gastric cancer[J]. Diagnostics (Basel), 2023, 13(7):1341.
[12]	Jalandra R, Dalal N, Yadav AK, et al. Emerging role of trimethylamine-N-oxide (TMAO) in colorectal cancer[J]. Appl Microbiol Biotechnol, 2021, 105(20):7651-7660.
[13]	Bardel̆cíková A, Šoltys J, Mojžiš J. Oxidative stress, inflammation and colorectal cancer: An overview[J]. Antioxidants (Basel), 2023, 12(4):901.
[14]	Yue C, Yang X, Li J, et al. Trimethylamine N-oxide prime NLRP3 inflammasome via inhibiting ATG16L1-induced autophagy in colonic epithelial cells[J]. Biochem Biophys Res Commun, 2017, 490(2):541-551.
[15]	Ke Y, Li D, Zhao M, et al. Gut flora-dependent metabolite trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stress[J]. Free Radic Biol Med, 2018, 116:88-100.
[16]	Man A, Zhou Y, Xia N, et al. Involvement of gut microbiota, microbial metabolites and interaction with polyphenol in host immunometabolism[J]. Nutrients, 2020, 12(10):3054.
[17]	Tarashi S, Siadat SD, Ahmadi BS, et al. Gut Bacteria and their metabolites: Which one is the defendant for colorectal cancer?[J]. Microorganisms, 2019, 7(11):561.
[18]	Drapala A, Szudzik M, Chabowski D, et al. Heart failure disturbs gut-blood barrier and increases plasma trimethylamine, a toxic bacterial metabolite[J]. Int J Mol Sci, 2020, 21(17):6161.
[19]	Sanchez-Alcoholado L, Ordonez R, Otero A, et al. Gut microbiota-mediated inflammation and gut permeability in patients with obesity and colorectal cancer[J]. Int J Mol Sci, 2020, 21(18):6782.
[20]	Yang S, Dai H, Lu Y, et al. Trimethylamine N-Oxide Promotes Cell Proliferation and Angiogenesis in Colorectal Cancer[J]. J Immunol Res, 2022, 2022:7043856.
[21]	Bhat MY, Singh LR, Dar TA. Trimethylamine N-oxide abolishes the chaperone activity of alpha-casein: An intrinsically disordered protein[J]. Sci Rep, 2017, 7(1):6572.
[22]	刘燕娥. 肠道菌群和氧化三甲胺与原发性肝癌的关系研究[D]. 长春: 吉林大学, 2023.
[23]	Cox IJ, Aliev AE, Crossey MM, et al. Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study[J]. World J Gastroenterol, 2016, 22(16):4191-4200.
[24]	Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: Inflammation mechanism, clinical prognostic, and potential as a therapeutic target[J]. Front Pharmacol, 2019, 10:1360. doi: 10.3389/fphar.2019.01360 pmid: 31803054
[25]	Huang JY, Luu HN, Butler LM, et al. A prospective evaluation of serum methionine-related metabolites in relation to pancreatic cancer risk in two prospective cohort studies[J]. Int J Cancer, 2020, 147(7):1917-1927. doi: 10.1002/ijc.32994 pmid: 32222976
[26]	Mirji G, Worth A, Bhat SA, et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer[J]. Sci Immunol, 2022, 7(75):eabn704.

TMAO在消化系统恶性肿瘤中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 15

编辑推荐

Metrics

本文评价

[1]	栗冲, 王硕, 张志华. 抗生素与肠道微生态的关系[J]. 临床荟萃, 2021, 36(4): 374-378.
[2]	杨智彬, 邵艳芳, 潘丽, 杨艳霞, 杨宇溪, 赵丽惠, 曾荣昆, 李阳, 王巧凤, 王聪, 马世武. 异甘草酸镁治疗抗结核药物性肝损伤疗效[J]. 临床荟萃, 2021, 36(11): 972-975.
[3]	孙振晓，于相芬. 多奈哌齐的不良反应[J]. 临床荟萃, 2020, 35(1): 80-83.
[4]	朱昭章, 周凡力, 卢岚. 中青年维持血液透析患者氧化三甲胺与轻度认知功能损害相关性临床研究[J]. 临床荟萃, 2019, 34(11): 991-994.
[5]	李玥，钱家鸣. 炎症性肠病合并艰难梭菌感染的研究进展[J]. 临床荟萃, 2018, 33(5): 394-397.
[6]	迟雁. 肠道微生态与炎症性肠病[J]. 临床荟萃, 2016, 31(8): 857-860.
[7]	刘岚剑，杨文娟. 重症肌无力合并胸腺病变患者血清乙酰胆碱受体抗体、肌联蛋白抗体和肌肉特异性酪氨酸激酶抗体的检测意义[J]. 临床荟萃, 2016, 31(7): 758-761.
[8]	李薇;蔡艺灵;杜鹃. 帕金森病痴呆影像学及治疗研究进展[J]. 临床荟萃, 2013, 28(7): 837-840.
[9]	王霞;梁卓燕;李慧芳. 盐酸多奈哌齐联合尼莫地平治疗血管性痴呆的临床观察[J]. 临床荟萃, 2012, 27(6): 482-484.
[10]	李彩霞;侯一平;廉会娟;任银祥. A型肉毒毒素对大鼠离体十二指肠平滑肌自发性收缩的影响[J]. 临床荟萃, 2012, 27(4): 312-316.
[11]	刘进;王磊. 胆碱酯酶对判断全身炎症反应综合征患者预后的价值[J]. 临床荟萃, 2012, 27(1): 48-49.
[12]	付黎明. 术后重症患者白蛋白及胆碱酯酶水平的变化及其临床意义[J]. 临床荟萃, 2011, 26(5): 398-400.
[13]	郑世良;刘美娟. 噻托溴胺对老年人慢性阻塞性肺疾病稳定期运动能力和肺功能的影响[J]. 临床荟萃, 2011, 26(19): 1722-1724.
[14]	喻东山. 胆碱酯酶抑制剂的非痴呆应用[J]. 临床荟萃, 2010, 25(3): 269-271.
[15]	贾庆灵;李志强;邱方;安媛;刘慧林. 卡巴胆碱治疗严重创伤患者胃肠功能障碍的随机对照研究[J]. 临床荟萃, 2010, 25(1): 72-74.